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Systemic sclerosis is a severe disease with poor progrosis because of cardiac involvement
which often goes with pericardial effusions. In our case report we show that pericardial
effusion may be the first sign of systemic sclerodermia.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
.1. Introduction
Systemic sclerosis is a connective tissue disease whose hall-
marks are autoimmunity, vasculopathy and fibrosis. It
involves the heart causing fibrosis and the pulmonary vascu-
lature causing pulmonary hypertension. Pulmonary arterial
hypertension (PAH) is an important clinical complication of
Ssc and a leading cause of mortality in this disease, the
reported prevalence ranging from 7% to 29%, depending on
study methodology, populations, and definitions used [1–4].
Small pericardial effusions are not uncommon in Ssc, and
pericarditis is a frequent post-mortem finding. Large hemo-
dynamically significant pericardial effusions with cardiac
tamponade are rare and have a poor outcome [5,6]. We report
a case of Ssc patient who presented with moderate pericar-
dial effusion. This case report aims to explore that pericardial
effusion can be the first sign of Ssc.2. Case report
In our study we would like to refer a case of a 49 years old
Caucasian woman who was seeking medical advice for thech Society of Cardiology.
. Kruzˇliak).first time due to dyspnea and intoleration of horizontal
position. At the time of admission the patient reported some
complaint about skin discolouration of her fingers by thick-
ening and pale. She had also some problems with swallowing
like dysphagia. She had a personal history of arterial hyper-
tension on medication with inhibitor of angiotensin convert-
ing enzyme beta-blockator, primary hypothyroidism treated
with L-thyroxin, and a state after hysterectomy in the past.
The patient’s temperature was 36.8 1C; blood pressure, 100/
70 mm Hg, pulse normal, heart rate, 85 beats per minute; and
respirations, 16. The patient was a well-developed, well-
nourished woman in no acute distress who was alert and
oriented. Examination of the head, eyes, ears, nose, and
throat were normocephalic, atraumatic. The nose and throat
were clear, and the tongue was normal in size. Scratch
purpura was absent. The jugular veins were without disten-
tion. No Kussmaul sign or x and y descent were appreciated.
The carotid pulses were full without bruits. There was no
palpable lymphadenopathy. The patient’s chest was without
abnormalities. Pulmonary and cardiac auscultation was with-
out pathology. Her abdomen was soft and nontender. There
was no splenomegaly. The bowel sounds were normal. Limbs
were without edema.Published by Elsevier Urban & Partner Sp.z o.o. All rights reserved..
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enon, the mentioned thickening around the nail bed and a
more extensive thicker area of the skin on the left forearm.
Laboratory examinations showed a slight leucocytosis, a
mild elevation of inflammatory parameters (FW, CRP).
Chest X-ray was without pathology and she showed a
normal ECG, the cardiothoracic index was also normal.
According to this clinical signs we suggested a form of
autoimmune disease and because of progressive dyspnea
made an echocardiographic examination which revealed a
moderate pericardial effusion without any signs of a cardiac
tamponade, and without echocardiographic signs of severe
pulmonary hypertension (Fig. 1). The results of this examina-
tions showed, that the clinical problems the patient pre-
sented, could be of autoimmune origin and suggested
sclerodermia.
The biochemical results such as highly positive antinuclear
antibodies/ANA/and also anti-Scl 70/antitDNA topoisomerase
I antibodies/completed the definitive diagnosis of systemic
sclerodermia.
After making the diagnosis we administered corticosteroids
and calcium channel blockers to improve the Raynauds
phenomenon and took away the betablocker from the med-
ication. The clinical status of the patient improved very
quickly, now she is without any serious symptoms and the
second ECHO after administration of steroids showed a
significant regression of the mentioned pericardial effusion.3. Discussion
Cardiovascular disease in patients with SS may be due to
either primary involvement of the heart by sclerosing disease
or a secondary involvement from disease of the kidney or
lungs. Cardiac involvement is a poor prognostic factor, but
diagnosis may be late or missing because of the frequent
discrepancy between clinical manifestation and cardiac
involvement, for this reason, resort to all available diagnostic
procedures is recommended to achieve an early diagnosis.
Cardiac signs include myocardial fibrosis, myocardial ische-
mia, conduction abnormalities such as left anteriorFig. 1 – Echocardiographic findings of moderate pericardial
effusion.hemiblock, systolic and diastolic dysfunction, pericarditis
and pericardial effusion [5,7].
Pericardial abnormalities in scleroderma have noted fibri-
nous pericarditis, pericardial adhesions, and pericardial effu-
sions at the time of autopsy. The incidence of pericardial
involvement in scleroderma is about 50% according to
autopsy results, but symptomatic pericarditis manifests in
about 16% of patients with diffuse scleroderma and in about
30% of patients with limited scleroderma. The clinically
evident pericardial effusion is rare in scleroderma, although
it can be detected in about 41% of patients with echocardio-
graphy [8]. However, clinically symptomatic pericardial
disease (5–16%) is much less frequent than autopsy-
demonstrated pericardial involvement (33–72%) [9–13]. Most
cases are asymptomatic, with premorbid symptoms being
reported in only 7–20% of patients [14]. Moreover, there also
have been large effusions causing tamponade and can even
occur prior to skin thickening and the diagnosis of sclero-
derma [8,15].
In our case pericardial effusion was the first sign of
scleroderma, without tamponade. Pericardial effusions are
also frequently associated with pulmonary hypertension and
may be the presenting feature of pulmonary hypertension in
scleroderma. Large pericardial effusions can lead to pericar-
dial tamponade and are a marker for poor outcome. If an
inflammatory component is thought to be the cause of the
effusion, immunosuppression therapy can markedly reduce
the volume of the effusion. Moreover, if clinical heart failure
is present, the effusion can be reduced with diuretics. Small,
asymptomatic pericardial effusions may occur if there is
cardiac involvement and should be observed. Oral predniso-
lone should be given for patients with pericardial effusions
causing marked symptoms. These patients are at risk of
developing cardiac tamponade. Patients with tamponade
should receive a pericardial window and systemic corticos-
teroids [12,13].4. Conclusion
Our case report showed that systemic sclerodermia can be
presented with a moderate to severe pericardial effusion with
or without any other clinical symptoms or systemic scler-
odermia. Therefore it is necessary to think about this disease
mainly in young women with progressive dyspnea without
any other signs of congestive heart failure and with an
echocardiographic picture that shows a mild to severe peri-
cardial effusion.
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